Compare · MRK vs PHVS
MRK vs PHVS
Side-by-side comparison of Merck & Company Inc. (MRK) and Pharvaris N.V. (PHVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and PHVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $314.90B, about 129.4x PHVS ($2.43B).
- Over the past year, MRK is up 59.4% and PHVS is up 51.8% - MRK leads by 7.6 points.
- MRK has been more active in the news (14 items in the past 4 weeks vs 12 for PHVS).
- MRK has more recent analyst coverage (25 ratings vs 14 for PHVS).
- Company
- Merck & Company Inc.
- Pharvaris N.V.
- Price
- $127.48-0.14%
- $34.91+3.67%
- Market cap
- $314.90B
- $2.43B
- 1M return
- +10.60%
- +10.98%
- 1Y return
- +59.45%
- +51.80%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 14
- 12
- Recent ratings
- 25
- 14
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
Latest MRK
- Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
- Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
- KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
- Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
- FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
- SEC Form 11-K filed by Merck & Company Inc.
Latest PHVS
- Chief Executive Officer Modig Berndt sold $80,154 worth of shares (2,292 units at $34.97) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 132,917 units (SEC Form 4)
- Wells Fargo initiated coverage on Pharvaris N.V. with a new price target
- Chief Medical Officer Lu Peng covered exercise/tax liability with 226 shares, decreasing direct ownership by 0.34% to 65,405 units (SEC Form 4) (tax withholding)
- SEC Form 144 filed by Pharvaris N.V.
- Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
- Director Schikan Johannes Gerardus Christiaan Petrus sold $1,331,496 worth of shares (37,600 units at $35.41) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 315,167 units (SEC Form 4)
- Chief Early Development Lesage Anne exercised 38,472 shares at a strike of $6.85 and sold $2,695,452 worth of shares (76,172 units at $35.39) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 58,750 units (SEC Form 4)
- Chief Early Development Lesage Anne exercised 2,300 shares at a strike of $4.73 and sold $161,560 worth of shares (4,600 units at $35.12) as part of a pre-agreed trading plan (SEC Form 4)
- Director Schikan Johannes Gerardus Christiaan Petrus sold $84,250 worth of shares (2,400 units at $35.10) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 352,767 units (SEC Form 4)
- Chief Medical Officer Lu Peng exercised 29,700 shares at a strike of $2.59 and sold $1,018,832 worth of shares (29,700 units at $34.30) as part of a pre-agreed trading plan (SEC Form 4)